Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial

IMPORTANCE: Although treatment with first-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies in patients with EGFR-mutated lung adenocarcinoma, recent single-arm studies have suggested that osimertinib plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Akamatsu, Hiroaki, Toi, Yukihiro, Hayashi, Hidetoshi, Fujimoto, Daichi, Tachihara, Motoko, Furuya, Naoki, Otani, Sakiko, Shimizu, Junichi, Katakami, Nobuyuki, Azuma, Koichi, Miura, Naoko, Nishino, Kazumi, Hara, Satoshi, Teraoka, Shunsuke, Morita, Satoshi, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791398/
https://www.ncbi.nlm.nih.gov/pubmed/33410885
http://dx.doi.org/10.1001/jamaoncol.2020.6758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791398/
https://www.ncbi.nlm.nih.gov/pubmed/33410885
http://dx.doi.org/10.1001/jamaoncol.2020.6758

Ejemplares similares